Last mentioned: 1d ago
Ethics Approval Received
NanoViricides announces National Ethics Committee approval for Phase II trial of NV-387 oral gummies for Ebola.
Outbreak Worsens
DRC public health institute reports 1,926 confirmed Ebola cases and 702 deaths, with spread to Haut-Uele and Tshopo provinces.
Africa CDC declares fastest-growing outbreak
Africa CDC states the outbreak is the fastest-growing Ebola epidemic on the continent as news of the spread to new provinces circulates.
Health workers protest
Ebola response workers protest outside three treatment centers in Bunia over unpaid wages; police disperse one demonstration at CME.
Government report released
A government report published late Wednesday confirms 1,759 total cases and 600 deaths, with two new suspected cases in Kisangani, Tshopo province—one with no known epidemiological link.
Clinical trials scheduled
Health workers prepare for Ebola clinical trials at the Evangelical Medical Center in Bunia, Ituri province.
Outbreak declared
DRC authorities declare a new Ebola outbreak caused by the Bundibugyo virus, after weeks of undetected transmission according to WHO.
As the DRC Ebola outbreak surpasses 1,900 cases with 702 fatalities, NanoViricides’ oral NV-387 gummies gain ethics approval for a Phase II trial. The chewable format could overcome logistical hurdles in resource-limited regions, potentially reshaping epidemic management if proven effective.
The public health crisis deepens as Ebola spreads to previously unaffected areas, with response hampered by funding gaps, worker protests, and no approved countermeasures.
This page surfaces every story mentioning Bundibugyo ebolavirus across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Bundibugyo ebolavirus was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |